Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion ...

Discover why Pfizer stock may be set for a bull run by 2026 with key wins, strong Q3 earnings, and growth drivers.

And one of them is pharmaceutical giant Pfizer ( PFE 0.04%). Now, with a major step along the path to entering this ...

If you own or are considering buying pharma laggards Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), and Merck (NYSE: ...

Pfizer PFE and AbbVie ABBV are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas ...

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare ...

Creador’s purchase of shares from Peak XV comes about a decade after the venture capital firm first invested in the company.

Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as ...

Triana Biomedicines has tapped Pfizer Ventures and a number of other existing and new investors to secure a $120 million ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics, as the Chinese biotech tacks on preclinical ...